share_log

Medtronic | 10-K: FY2024 Annual Report

Medtronic | 10-K: FY2024 Annual Report

美敦力 | 10-K：2024财年年报
美股SEC公告 ·  2024/06/21 04:24

Moomoo AI 已提取核心信息

Medtronic plc reported fiscal year 2024 results with revenue increasing 4% to $32.4 billion, driven by growth across most businesses including Surgical, Cranial & Spinal Technologies, Diabetes, and Cardiac Pacing. Net income was $3.7 billion with diluted earnings per share of $2.76, compared to $3.8 billion and $2.82 in the prior year.The Cardiovascular Portfolio grew 3% to $11.8 billion, with strong performance in Micra, TAVR, and Perfusion. Neuroscience Portfolio increased 5% to $9.4 billion, while Medical Surgical Portfolio rose 5% to $8.4 billion. The Diabetes Operating Unit showed significant improvement with 10% growth to $2.5 billion, driven by international expansion of the MiniMed 780G insulin pump system.Looking ahead, the company faces potential headwinds from competitive pressures, geographic macro-economic risks, and supply chain challenges. Medtronic maintains a strong financial position with $1.3 billion in cash and $6.7 billion in current investments. The company returned $5.7 billion to shareholders through dividends of $3.7 billion and share repurchases of $2.1 billion during fiscal year 2024.
Medtronic plc reported fiscal year 2024 results with revenue increasing 4% to $32.4 billion, driven by growth across most businesses including Surgical, Cranial & Spinal Technologies, Diabetes, and Cardiac Pacing. Net income was $3.7 billion with diluted earnings per share of $2.76, compared to $3.8 billion and $2.82 in the prior year.The Cardiovascular Portfolio grew 3% to $11.8 billion, with strong performance in Micra, TAVR, and Perfusion. Neuroscience Portfolio increased 5% to $9.4 billion, while Medical Surgical Portfolio rose 5% to $8.4 billion. The Diabetes Operating Unit showed significant improvement with 10% growth to $2.5 billion, driven by international expansion of the MiniMed 780G insulin pump system.Looking ahead, the company faces potential headwinds from competitive pressures, geographic macro-economic risks, and supply chain challenges. Medtronic maintains a strong financial position with $1.3 billion in cash and $6.7 billion in current investments. The company returned $5.7 billion to shareholders through dividends of $3.7 billion and share repurchases of $2.1 billion during fiscal year 2024.
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点